Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

K-Clip annuloplasty system for tricuspid regurgitation by Shanghai Huihe Medical Technology Co.

Cardiologists detail world's first use of new annuloplasty system for tricuspid regurgitation

Early data suggest the new transcatheter tricuspid valve repair device could make a big impact on patient care, but additional research is still necessary. 

VDyne Valve for transcatheter tricuspid valve replacement

Cardiologists highlight early success of new TTVR system for tricuspid regurgitation

Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.

Abbott TriClip device for TEER

TriClip triumphs: Tricuspid edge-to-edge repair linked to strong 30-day outcomes in real-world setting

The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

TricValve Transcatheter Bicaval Valves System and HeartMate II LVAD

Cardiologists shed new light on treating severe tricuspid regurgitation in high-risk heart failure patients

The 80-year-old patient was experiencing severe TR and already had a HeartMate II LVAD. 

The LuX-Valve Plus transcatheter tricuspid valve replacement (TTVR) device

Cardiologists make history, perform TTVR with new-look valve for first time in U.S.

The new valve was placed inside the damaged valve via a catheter that is inserted through a small incision in the patient's neck. 

Paul Sorajja, MD, director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital, was the principal investigator for the late-breaking TRILUMINATE pivotal trial at the American College of Cardiology (ACC) 2023 meeting and explains details of this landmark trial. #ACC #ACC23 #triluminate

TRILUMINATE trial may pave the way for FDA clearance for tricuspid valve clip device

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

ACC.23 Together with the World Congress of Cardiology

Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair and statins

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

Edwards Lifesciences Corporation has shared new one-year data on the safety and effectiveness of its Evoque transcatheter tricuspid valve replacement (TTVR) system among patients with tricuspid regurgitation (TR)

Edwards shares new one-year data on transcatheter tricuspid valve replacement

The new findings, presented at the PCR London Valves 2022 conference, focused on mortality and heart failure hospitalization rates.